Source - RNS
RNS Number : 1857H
Arix Bioscience Plc
05 June 2017
 

 

Results of Annual General Meeting

 

LONDON, 5 June, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, announces that its Annual General Meeting (the "Meeting") was held on Monday 5 June 2017 at 2pm (London time). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 26 April 2017 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 14 and 19 were passed as ordinary resolutions. Resolutions 15 to 18 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.  

 

No 

RESOLUTION

VOTES
FOR

%

VOTES
AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES
WITHHELD

1

To receive the Directors' report and the accounts for the Company for the period ended 31 December 2016

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

2

To approved the Directors' Remuneration Policy

41,408,348

88.59

5,333,387

11.41

46,741,735

48.64%

942

3

To re-elect Dr Joseph Anderson as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

4

To re-elect Sir John Banham as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

5.

To re-elect Professor Sir Chris Evans as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

6

To re-elect Dr Franz Humer as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

7

To re-elect Lord John Hutton of Furness as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

8

To re-elect Professor Trevor Jones as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

9

To re-elect Jonathan Peacock as a Director

46,251,849

98.95

490,200

1.05

46,742,049

48.64%

628

10.

To Re-elect James Rawlingson as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

11.

To re-elect David U'Prichard as a Director

46,742,049

100.00

0

0.00

46,742,049

48.64%

628

12

To re-appoint PwC LLP as auditors of the Company

46,741,735

100.00

0

0.00

46,741,735

48.64%

942

13

To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors

46,741,735

100.00

0

0.00

46,741,735

48.64%

942

14

To authorise the Directors to allot shares

46,742,049

100.00

628

0.00

46,742,677

48.64%

0

15

To authorise the Directors to disapply statutory pre-emption rights in respect of 5% of the Company's issued share capital

44,140,479

94.43

2,601,570

5.57

46,742,049

48.64%

628

16

To authorise the Directors to disapply statutory pre-emption rights in respect of an additional 5% of the Company's issued share capital

43,277,458

92.59

3,464,591

7.41

46,742,049

48.64%

628

17

To authorise the Company to buy back shares

46,740,165

99.99

2,512

0.01

46,742,677

48.64%

0

18

To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice

46,742,677

100.00

0

0.00

46,742,677

48.64%

0

19

To authorise the Company to purchase its own Deferred Shares

46,741,735

100.00

942

0.00

46,742,677

48.64%

0

Notes:

1.    Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.

2.    A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

3.    The number of shares in issue at 6:00 p.m. on 1 June 2017 was 96,091,083 (the "Share Capital"). The Company does not hold any shares in treasury.

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism which can be accessed at www.hemscott.com/nsm.do

 

For more information, please contact:

 

Arix Bioscience plc

Joe Anderson, CEO

+44 (0) 20 7290 1052

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGOKPDQQBKDBAK